Do microRNAs control inflammatory mediator production by airway epithelial cells from patients with asthma and COPD?

Conditions: asthma
COPD
10024967

Registration Number: NL-OMON31684

Lead Sponsor: Academisch Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 60

Inclusion Criteria

Asthma: non-smoking, allergic, intermittent to mild persistent asthma (history of episodic wheeze and shortness of breath). FEV1 predicted > 70% and PC20 histamine between 0.25 to 8 mg/ml.
COPD: middle-age onset of symptoms, cigarette consumption of at least 15 pack-years and a post-bronchodilator FEV1/VC ratio smaller than 0.7. Reversibility in FEV1 assessed after the apropriate abstaining of bronchodilators, and measured follwing high dose of beta2-agonist inhalation was below 11% of predicted.
Healthy individuals: no lung pathology

Exclusion Criteria

Exacerbation requiring oral steroids or antibiotics for 3 months before the study and no lower respiratory tract infection for 4 weeks before the study. Inhaled corticosteroids, antibiotics, theophylline, sodium cromoglycate, or antileukotrienes were not allowed 4 weeks before and during the study. Specific exclusion criteria: for COPD patients: allergy; for asthma patients: smoking

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>With this project we will analyze around five proteins in a semi-quantitative<br /><br>manner and determine the microRNA profiles in airway epithelial cells from<br /><br>patients with asthma or COPD or that of healthy individuals. In both analyses<br /><br>we will use endogenous standards allowing us to compare the analyses between<br /><br>the study groups. These analyses will be linked to clinical details.</p><br>

Secondary Outcome Measures